Status:
COMPLETED
Piloting "Signs of Safety": A Deaf-Accessible Therapy Toolkit for Alcohol Use Disorder and Trauma
Lead Sponsor:
University of Massachusetts, Worcester
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcohol Use Disorder
Post Traumatic Stress Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The U.S. Deaf community - more than 500,000 Americans who communicate using American Sign Language (ASL) - experiences nearly triple the rate of lifetime problem drinking and twice the rate of trauma ...
Detailed Description
The U.S. Deaf community - 500,000+ Americans who communicate using American Sign Language (ASL) - experiences nearly triple the rate of lifetime problem drinking compared to the general population and...
Eligibility Criteria
Inclusion
- Self-identification as a Deaf ASL user
- Age 18 or older
- Past-month alcohol consumption, as measured by the Alcohol Use Disorder Identification Test
- Subthreshold or full PTSD on the PTSD Checklist for DSM-5 (past-month referent time period; "subthreshold" = endorsement of at least two B-E criteria at a severity of "moderate" or higher)
- Ability to attend weekly study sessions at one of three study locations (Eastern, Central, or Western MA)
- Ability to access a videophone (the standard telecommunication device for the Deaf community)
Exclusion
- Participation in concurrent therapies (Note: Participants in both study conditions will be asked to refrain from concurrent formal psychotherapy; however, aligning with the Seeking Safety model, AA/NA/DRA attendance will be encouraged and attendance will be tracked as a potential outcome mediator).
- Members of the following special populations: Adults unable to consent; Individuals younger than 18; Prisoners; Pregnant women (Note: We will not knowingly include pregnant women as participants; however, we will not assess participants' pregnancy status.)
- Exclusion criteria are intentionally minimal to recruit a diverse sample. Other behavioral health comorbidities (e.g., mood/anxiety disorders, substance use disorders other than AUD) will not be excluded, given high rates of comorbidity.
Key Trial Info
Start Date :
June 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03845985
Start Date
June 3 2019
End Date
July 31 2022
Last Update
March 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Massachusetts Medical School
Worcester, Massachusetts, United States, 01655